Following an Experts Knowledge Share meeting during ESMO 2019, NET CONNECT has transformed the educational programme into an interactive e-learning.

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED. 

 

Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.

Asst. Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novartis, Pfizer, Ipsen. 

Dr Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).

Dr Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi. 

Prof. Marianne Pavel is the Chair of Endocrinology at the Department of Medicine 1, University of Erlangen, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology/diabetes in 2001; she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital, Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. Her major focus in medicine is neuroendocrine tumors for more than 20 years. She has conducted numerous clinical trials in the field of NET. She is involved in the activities from ENETS since 2005 and is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Since April 2014 she is a member of the Executive Committee of ENETS and has recently been elected as chair of ENETS up from 2020. She is involved in scientific and educational activities in NET from different societies including German Cancer Foundation and ESMO.
Programme summary
Take the e-learning now
Other modules in this series
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Ipsen
Accreditation
EACCME
This course has been accredited by EACCME® for 1 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
interactive-patient-case Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
other Other
Oncology 
Lung cancer survey: Patient views on biomarker testing

Share the survey with patients with lung cancer and their caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
podcast Podcast
Oncology 
Precision oncology approaches in lung cancer

Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.